Peptide LibraryResearch statistics
Enlicitide research: publications and trials
At a glance
Publications, all years
45
Since 2023
Publications in 2026 so far
32
Through November 1, 2026
Human clinical research
15.8%
6 of 38 classified
Registered clinical trials
34
ClinicalTrials.gov
Randomized controlled trials
5
Publications reporting an RCT in people
Systematic reviews and meta-analyses
8
Preclinical studies
2.6%
0 animal · 0 in vitro · 1 computational
Records that only mention it
11
Not counted above
Status in the library: FDA-approved. 7 publications are not yet classified by study type.
What to keep in mind
- Some completed trials have neither posted results nor a linked results publication.
Publications by year
Enlicitide publications by year and evidence
Show the data
| Year | Human clinical research | Preclinical (animal, in vitro, computational) | Reviews and meta-analyses | Other and not yet classified | Total |
|---|---|---|---|---|---|
| 2023 | 2 | 0 | 1 | 0 | 3 |
| 2024 | 0 | 0 | 4 | 0 | 4 |
| 2025 | 0 | 0 | 4 | 2 | 6 |
| 2026 (to date) | 4 | 1 | 16 | 11 | 32 |
Study types
| Review | 17 |
|---|---|
| Not yet classified | 7 |
| Editorial, letter or other | 5 |
| Randomized controlled trial | 5 |
| Meta-analysis | 4 |
| Systematic review | 4 |
| Other clinical trial | 1 |
| Computational study | 1 |
| Correction or retraction notice | 1 |
Research areas
From MeSH major topics. A paper can be in several areas.
| Metabolic health | 27 |
|---|---|
| Cardiovascular | 15 |
Registered clinical trials
16 of 24 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.
Completed: 26 · Active, not recruiting: 5 · Recruiting: 3
Phase 1: 24 · Phase 2: 2 · Phase 2 / Phase 3: 1 · Phase 3: 7
Human trials and evidence reviews
Meta-analyses, systematic reviews and trials in people, newest first.
- Efficacy and Safety of Enlicitide in Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Endocrinology, diabetes & metabolism · November 1, 2026 · Meta-analysis · cited 0 times · open access
PMID 42867105 · DOI 10.1002/edm2.70358 · Reviews and meta-analyses
- Oral PCSK9 inhibitors for elevated LDL-C: A systematic review and meta-analysis of randomized trials.
American journal of preventive cardiology · May 2, 2026 · Meta-analysis · cited 2 times · open access
PMID 42395082 · DOI 10.1016/j.ajpc.2026.101659 · Reviews and meta-analyses
- Lipoprotein(a) reduction with inclisiran, alirocumab, evolocumab, enlicitide, and lerodalcibep: A systematic review and meta-analysis of randomized controlled trials.
Journal of clinical lipidology · April 1, 2026 · Meta-analysis · cited 8 times
PMID 42025558 · DOI 10.1016/j.jacl.2026.03.019 · Reviews and meta-analyses
- Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic Review and Meta-Analysis.
Advances in therapy · November 25, 2025 · Meta-analysis · cited 6 times · open access
PMID 41288928 · DOI 10.1007/s12325-025-03418-x · Reviews and meta-analyses
- Comparative efficacy and safety of orally administered PCSK9 inhibitors in patients with Hypercholesterolaemia: a dose-stratified systematic review and network meta-analysis.
Endocrine · October 6, 2026 · Systematic review · cited 0 times
PMID 42837061 · DOI 10.1007/s12020-026-04805-2 · Reviews and meta-analyses
- Meta-Analysis of Oral PCSK9 Inhibitors for Hypercholesterolemia in Adults: A Systematic Review and GRADE Assessment.
Cardiology in review · June 10, 2026 · Systematic review · cited 0 times
PMID 42269009 · DOI 10.1097/crd.0000000000001357 · Reviews and meta-analyses
- Efficacy and Safety of Oral PCSK9 Inhibitors: Insights from a Meta-analysis of RCTS.
European journal of preventive cardiology · May 22, 2026 · Systematic review · cited 5 times · open access
PMID 42169510 · DOI 10.1093/eurjpc/zwag273 · Reviews and meta-analyses
- Safety and Efficacy of Oral PCSK9 Inhibitors in Hypercholesterolemia: A Systematic Review and Network Meta-Analysis.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · February 12, 2026 · Systematic review · cited 3 times
PMID 41690582 · DOI 10.1016/j.eprac.2026.02.002 · Reviews and meta-analyses
- Phase 3 study results for oral PCSK9 inhibition with enlicitide.
Med (New York, N.Y.) · April 1, 2026 · Randomized controlled trial · cited 3 times
PMID 41966715 · DOI 10.1016/j.medj.2026.101097 · Human clinical research
- Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin Therapies: A Phase 3 Randomized Clinical Trial.
Journal of the American College of Cardiology · March 30, 2026 · Randomized controlled trial · cited 19 times · open access
PMID 42017875 · DOI 10.1016/j.jacc.2026.03.036 · Human clinical research
Most cited
By OpenAlex citation count. Citations measure attention, not quality or correctness.
- Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616.
Journal of the American College of Cardiology · March 6, 2023 · Randomized controlled trial · cited 223 times · open access
PMID 36889610 · DOI 10.1016/j.jacc.2023.02.018 · Human clinical research
- Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor.
Circulation · May 1, 2023 · Other clinical trial · cited 171 times · open access
PMID 37125593 · DOI 10.1161/circulationaha.122.063372 · Human clinical research
- Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial.
JAMA · January 1, 2026 · Randomized controlled trial · cited 68 times · open access
PMID 41206969 · DOI 10.1001/jama.2025.20620 · Human clinical research
- A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide.
The New England journal of medicine · February 1, 2026 · Randomized controlled trial · cited 57 times
PMID 41879224 · DOI 10.1056/nejmoa2511002 · Human clinical research
- From lead to market: chemical approaches to transform peptides into therapeutics.
Trends in biochemical sciences · February 25, 2025 · Review · cited 52 times
PMID 40011178 · DOI 10.1016/j.tibs.2025.01.009 · Reviews and meta-analyses
Latest publications
- Efficacy and Safety of Enlicitide in Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Endocrinology, diabetes & metabolism · November 1, 2026 · Meta-analysis · cited 0 times · open access
PMID 42867105 · DOI 10.1002/edm2.70358 · Reviews and meta-analyses
- Enlicitide: The First Oral PCSK9i for Lowering Low-Density Lipoprotein Cholesterol.
The Annals of pharmacotherapy · October 14, 2026 · Review · cited 0 times
PMID 42870623 · DOI 10.1177/10600280261494015 · Reviews and meta-analyses
- Comparative efficacy and safety of orally administered PCSK9 inhibitors in patients with Hypercholesterolaemia: a dose-stratified systematic review and network meta-analysis.
Endocrine · October 6, 2026 · Systematic review · cited 0 times
PMID 42837061 · DOI 10.1007/s12020-026-04805-2 · Reviews and meta-analyses
- Oral PCSK9 inhibitors: closing the gap between potency and practicality.
Current opinion in lipidology · September 18, 2026 · Review · cited 0 times
PMID 42755338 · DOI 10.1097/mol.0000000000001061 · Reviews and meta-analyses
- Enlicitide
September 15, 2026 · Review · cited 0 times · open access
PMID 42766709 · Reviews and meta-analyses
- Evaluating enlicitide decanoate: first oral PCSK9 inhibitor for the treatment of adults with hypercholesterolemia.
Expert opinion on pharmacotherapy · September 15, 2026 · Review · cited 0 times
PMID 42709041 · DOI 10.1080/14656566.2026.2732054 · Reviews and meta-analyses
- Enlicitide Decanoate.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · September 10, 2026 · Not yet classified · cited 0 times
PMID 42717287 · DOI 10.1093/ajhp/zxag264 · Not yet classified
- Comment on "Lipoprotein(a) reduction with inclisiran, alirocumab, evolocumab, enlicitide, and lerodalcibep: A systematic review and meta-analysis of randomized controlled trials".
International journal of cardiology. Cardiovascular risk and prevention · September 9, 2026 · Editorial, letter or other · cited 0 times · open access
PMID 42774982 · DOI 10.1016/j.ijcrp.2026.200694 · Commentary and other
- Correction to "Discovery Process of Enlicitide, a Highly Engineered Macrocyclic Peptide Therapeutic, Through Issue Driven Fragment-Based Synthetic Assembly and SAR".
Journal of medicinal chemistry · September 1, 2026 · Correction or retraction notice · cited 0 times
PMID 42720501 · DOI 10.1021/acs.jmedchem.6c02516 · Notices
- Enlicitide
August 27, 2026 · Review · cited 0 times · open access
PMID 42709929 · Reviews and meta-analyses
How this is counted
PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology
Search terms: Enlicitide; Enlicitide chloride; Enlicitide decanoate; Lipfendra; MK-0616
((TITLE_ABS:"Enlicitide" OR CHEM:"Enlicitide") OR (TITLE_ABS:"Enlicitide chloride" OR CHEM:"Enlicitide chloride") OR (TITLE_ABS:"Enlicitide decanoate" OR CHEM:"Enlicitide decanoate") OR (TITLE_ABS:"Lipfendra" OR CHEM:"Lipfendra") OR (TITLE_ABS:"MK-0616" OR CHEM:"MK-0616" OR TITLE_ABS:"MK0616" OR CHEM:"MK0616")) AND SRC:MED
Cite this page
Peptide Library. (2026, November 2). Enlicitide research statistics (Version weekly-2026-11-01) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/enlicitide